Your browser doesn't support javascript.
loading
Development of an overactive bladder assessment tool (BAT): A potential improvement to the standard bladder diary.
Kelleher, Con; Chapple, Christopher; Johnson, Nathan; Payne, Christopher; Homma, Yukio; Hakimi, Zalmai; Siddiqui, Emad; Evans, Christopher; Egan, Shayna; Kopp, Zoe.
Afiliación
  • Kelleher C; Department of Obstetrics and Gynecology, Guy's and St Thomas' Hospitals, London, UK.
  • Chapple C; Department of Urology, The Royal Hallamshire Hospital, Sheffield Teaching Hospitals, Sheffield, UK.
  • Johnson N; Endpoint Outcomes, Long Beach, California.
  • Payne C; Vista Urology and Pelvic Pain Partners, San Jose, California.
  • Homma Y; Japanese Red Cross Medical Center, Tokyo, Japan.
  • Hakimi Z; Astellas Pharma Europe Ltd, Leiden, Netherlands.
  • Siddiqui E; Astellas Pharma Europe Ltd, Chertsey, UK.
  • Evans C; Endpoint Outcomes, Boston, Massachusetts.
  • Egan S; Endpoint Outcomes, Long Beach, California.
  • Kopp Z; Endpoint Outcomes, Boston, Massachusetts.
Neurourol Urodyn ; 37(5): 1701-1710, 2018 06.
Article en En | MEDLINE | ID: mdl-29360189
AIMS: To develop a comprehensive patient-reported bladder assessment tool (BAT) for assessing overactive bladder (OAB) symptoms, bother, impacts, and satisfaction with treatment. METHODS: Subjects were consented and eligibility was confirmed by a recruiting physician; subjects were then scheduled for in-person interviews. For concept elicitation and cognitive interviews, 30 and 20 subjects, respectively, were targeted for recruitment from US sites. All interviews were conducted face-to-face, audio-recorded, transcribed verbatim, anonymized, and analyzed using a qualitative data analysis software program. A draft BAT was created based on the results of the concept elicitation interviews and further revised based on cognitive interviews as well as feedback from an advisory board of clinical and patient-reported outcome (PRO) experts. RESULTS: Nocturia, daytime frequency, and urgency were reported by all subjects (n = 30, 100.0%), and incontinence was reported by most subjects (n = 25, 83.3%). The most frequently reported impacts were waking up to urinate (n = 30, 100.0%), embarrassment/shame (n = 24, 80.0%), stress/anxiety (n = 23, 76.7%), and lack of control (n = 23, 76.7%). Following analysis, item generation, cognitive interviews, and advisory board feedback, the resulting BAT contains four hypothesized domains (symptom frequency, symptom bother, impacts, and satisfaction with treatment) and 17 items with a 7-day recall period. CONCLUSIONS: The BAT has been developed in multiple stages with input from both OAB patients and clinical experts following the recommended processes included in the FDA PRO Guidance for Industry. Once fully validated, we believe it will offer a superior alternative to use of the bladder diary and other PROs for monitoring OAB patients in clinical trials and clinical practice.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Incontinencia Urinaria / Vejiga Urinaria Hiperactiva / Nocturia Tipo de estudio: Guideline / Qualitative_research Aspecto: Patient_preference Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Neurourol Urodyn Año: 2018 Tipo del documento: Article Pais de publicación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Incontinencia Urinaria / Vejiga Urinaria Hiperactiva / Nocturia Tipo de estudio: Guideline / Qualitative_research Aspecto: Patient_preference Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Neurourol Urodyn Año: 2018 Tipo del documento: Article Pais de publicación: Estados Unidos